Market revenue in 2023 | USD 18.7 million |
Market revenue in 2030 | USD 70.8 million |
Growth rate | 21% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 65.78% in 2023. Horizon Databook has segmented the UAE cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
The cell and gene therapy CDMO market is expected to grow steadily in the UAE due to the rising prevalence of several chronic diseases, growing investments in complex biologic molecules development, a supportive regulatory environment, entry of new players, and growing year-on-year investments of foreign pharmaceutical companies & CDMOs.
Moreover, the market is fueled by domestic players who are expanding their pharmaceutical production capacities & geographical presence through various strategies. Such factors are expected to support the production of pharmaceutical products in the country.
The number of CDMOs in the UAE has been increasing since 2000. The country offers favorable incentive policies and increased healthcare spending that have attracted leading pharmaceutical companies, such as Pfizer, AstraZeneca, and Amgen.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into UAE cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account